🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,557 results for “placebo” Clear

  1. ALG-000184, ALG-000184 Placebo, Tenofovir Disoproxil Placebo, Tenofovirdisoproxil Amarox 245 mg Filmtabletten

    Aligos Therapeutics

    Chronic Hepatitis B Virus Infection

    phase 2 small molecule active

    1 trial

  2. ALKS 2680, ALKS 2680, Placebo to match ALKS 2680, ALKS 2680

    Alkermes Pharma Ireland

    Idiopathic Hypersomnia (IH)

    phase 2 small molecule active

    1 trial

  3. ALXN 2040, Placebo matching ALXN2040

    Alexion Europe SAS

    Geographic atrophy (GA) secondary to Age-related Macular Degeneration (AMD)

    phase 2 small molecule active

    1 trial

  4. ALXN 2050, ALXN2050 Placebo Tablets

    Alexion Europe SAS

    Lupus Nephritis (LN) Immunoglobulin A Nephropathy (IgAN)

    phase 2 small molecule active

    1 trial

  5. ALXN2420, OCTREOTIDE ACETATE, OCTREOTIDE ACETATE, LANREOTIDE ACETATE, LANREOTIDE ACETATE, matching placebo for ALXN2420, LANREOTIDE ACETATE, OCTREOTIDE ACETATE

    Alexion Europe SAS

    Acromegaly

    phase 2 small molecule active

    1 trial

  6. AMG 133, Placebo for AMG 133

    Amgen

    Overweight and Obesity

    phase 2 small molecule active

    1 trial

  7. AP02 High, AP02 Low, AP02 Placebo

    Lacuna Pharma Pty Ltd

    Idiopathic Pulmonary Fibrosis (IPF)

    phase 2 small molecule active

    1 trial

  8. AP1189 Tablet, AP1189 Tablet, AP1189 Tablet, Matching Placebo (tablets), Methotrexat-Ebewe, 2,5 mg, tabletki

    Lacuna Pharma Pty Ltd

    Rheumatoid Arthritis

    phase 2 small molecule active

    1 trial

  9. AP31969, AP31969, The placebo tablets contain the same excipient as in the active IMP, but without AP31969. All tablet strengths containing AP31969 as well as placebo tablets are visually identical., AP31969, AP31969

    Lacuna Pharma Pty Ltd

    Atrial fibrillation

    phase 2 small molecule active

    1 trial

  10. AP707, Placebo

    Lacuna Pharma Pty Ltd

    Borderline personality disorder

    phase 2 small molecule active

    1 trial

  11. APG777, Placebo

    Apogee Therapeutics

    Atopic Dermatitis

    phase 2 small molecule active

    1 trial

  12. ART27.13, Placebo, ART27.13

    ARTELO BIOSCIENCES, INC.

    Cancer Anorexia

    phase 2 small molecule active

    1 trial

  13. ATI-045, Placebo to ATI-045

    Aclaris Therapeutics

    Atopic dermatitis

    phase 2 small molecule active

    1 trial

  14. AXATILIMAB, Placebo

    Syndax Pharmaceuticals

    Idiopathic pulmonary fibrosis

    phase 2 small molecule active

    1 trial

  15. AZD0292, Placebo for AZD0292

    AstraZeneca AB

    Bronchiectasis with chronic pseudomonas aeruginosa colonization

    phase 2 small molecule active

    1 trial

  16. AZD0780, AZD0780, AZD0780 Placebo, AZD0780

    AstraZeneca AB

    Dyslipidemia Dyslipidemias are alterations to the plasma lipid profile associated often with clinical condition. A common form of dyslipidemia is Hypercholesterolemia due to high level of LDL-cholesterol, which is a major risk factor for Cardiovascular Disease (CVD), such as Ischemic Heart Disease and Ischemic Stroke. CVD is a leading cause of global mortality and a contributor to disability.

    phase 2 small molecule active

    1 trial

  17. AZD1163 Placebo, AZD1163

    AstraZeneca AB

    Rheumatoid arthritis

    phase 2 small molecule active

    1 trial

  18. AZD4604, AZD4604 Placebo, AZD4604

    AstraZeneca AB

    Adult Patients with Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA

    phase 2 small molecule active

    1 trial

  19. AZD4604, Azd4604 placebo, AZD4604

    AstraZeneca AB

    Asthma

    phase 2 small molecule active

    1 trial

  20. AZD5004, AZD5004, AZD5004, Rybelsus 14 mg tablets, Placebo to match AZD5004 (PTM) film-coated tablets, Rybelsus 7 mg tablets, Rybelsus 3 mg tablets

    AstraZeneca AB

    Type 2 Diabetes Mellitus

    phase 2 small molecule active

    1 trial

  21. AZD5004, Placebo to match AZD5004 film coated tablet, AZD5004, AZD5004

    AstraZeneca AB

    Participants living with Obesity or Overweight with at least 1 comorbidity

    phase 2 small molecule active

    1 trial

  22. AZD5462, AZD5462, The AZD5462 film-coated tablet placebo contains microcrystalline cellulose, magnesium stearate, polyvinyl alcohol, titanium dioxide, macrogol (polyethylene glycol) and talc. It is supplied in the same pack as the active and should be stored according to instructions on the label., AZD5462

    AstraZeneca AB

    Chronic Heart Failure

    phase 2 small molecule active

    1 trial

  23. AZD6793, AZD6793 Placebo, AZD6793, AZD6793

    AstraZeneca AB

    Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)

    phase 2 small molecule active

    1 trial

  24. AZD7798 Placebo, AZD7798

    AstraZeneca AB

    Crohn's Disease

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources